To The Moon

Eli Lilly has been having major wins since their earnings. They’re drugs are no longer in shortage, Zepound was found to have cardiovascular benefits, and their once a week insulin is showing equal results to daily insulin injections.The cardiovascular benefits from zepound is huge because patient insurances are more likely to cover drugs like this, without patients having to try other medications since it’s an actual benefit that no other fat loss meds have and it help lower the risk of their patients being in the hospital, which will save insurance companies more money at the end.The weekly insulin is HUGE. The biggest complaints patients have is the amount of times they have to inject themselves throughout the day. The benefit this will have, is that both type 1 and type 2 diabetics can

Buy both. No need to choose

$Eli Lilly(LLY)$  Wow. Double beat. Previous Full Year guide up now guiding up again.  India approval.  What's coming next? Stock split?

$Novo-Nordisk A/S(NVO)$ Definitely undervalued. The market makers are finding a reason to push the price down. Sales of Ozempic & Wegovy are still pretty stellar. Missed analyst estimates??!! Come on.🙄 Be patient. There's a reason why prices are being pushed down. Definitely bullish.

Considering Novo Nordisk (NVO) and Eli Lilly (LLY) before earnings? Both have strong growth prospects, especially in diabetes care. Assess their financials and market position for a potentially rewarding investment. [Great][Great][Great]$Novo-Nordisk A/S(NVO)$ $Eli Lilly(LLY)$

$Novo-Nordisk A/S(NVO)$ This feels undervalued compared to $Eli Lilly(LLY)$ LLY. Little debt, yearly earnings exceeding 50B (10x that of LLY for ‘23). I get LLY has other drugs in the pipeline aside from weight loss / diabetes, but they don’t seem as lucrative as the weight loss market. Anyone know why else LLY is valued much higher other than the fact it’s a US company? Not saying comparatively LLY is a bad choice, just that NVO books look better. LLY sales as much as PFE and its value is like 5X of PFE. NVO seems slightly undervalued but LLY definitely way overvalued.

$Novo-Nordisk A/S(NVO)$ Earnings today -estimates are upbeat for - revenue beat - earnings beat - improved GRoss Profit- guidance upgrade based of improved supply chain - so the key are any new disclosures on new market launches, acquisition update and new FDA approvals - feels positive -time for upside surprise and make shorts scramble 👍🏻😁

$Eli Lilly(LLY)$ Now it's time for some facts.Lly Earnings are forecasted to increase for the next 2 quarters going forward.Based on analyst ratings, Eli Lilly’s 12 month average price target is $943.00 Eli Lilly has a 17% upside potential based on the analysts' average target price and the current price of $804. Now I believe this analyst rating may have occurred before the price drop. Based on the original 7.3% upside, the stock was probably around $880 a share when they were calculating the upside potential. On the low side I have seen other analysts who say the average Target prices $858 a share. Still with a 7% upside potential.Regardless, that should not change the outlook consensus which is based on sales projections. so in theory, the upsid

$Eli Lilly(LLY)$ In Big Pharma's growth rankings Eli Lilly took top spot away from Novo Nordisk in Q1and they will do it again in Q2.NVO $Novo-Nordisk A/S(NVO)$ missed. Lilly won't missFacts matter! Look at last quarter to see how it played out.Q1: Novo Nordisk dropped out of the top spot with its 22% YOY increaseLilly took over as No. 1 thanks to its 28% quarterly boost.They will do it again and beat NVOThink Winnie The Pooh GIF

$Eli Lilly(LLY)$ is scheduled to report its results for period ending 30 June 2024 on 08 August 2024 before the market open. Market is expecting LLY to show a rise in quarterly revenue with a 19.3% increase in revenue to $9.919 billion from $8.31 billion compared to same period one year ago. Earnings per share estimate for Eli Lilly is $2.75. Benefit From Novo Weight Loss Medicine Wegovy Shortage While the Food and Drug Administration removed Eli Lilly's competing weight loss medicine Zepbound from its shortage list last week, most dosage versions of Wegovy remain in shortage. So this would be something that investors could be looking out for $Novo-Nordisk A/S(NVO)$ result reporting on Wednesday whether NV

$Eli Lilly(LLY)$  Earnings out pre market on 8 aug. $LLY will continue to dominate the obesity market and associated secondary indications over time. Company has the lead and has now become the most valuable large cap biotech company.  Invest in the winner 🏆 

😀Hi Tigers,We invite you to take a closer look at the possible winners by EPS in the Q2 earnings season.In this post, we have highlighted the top 20 stocks by market capitalization with an estimated higher EPS ahead of their earnings in the period from August 5 to August 9.1.Why EPS Matters?Earnings per share(EPS), refers to the income per share brought to investors/shareholders in the open market.EPS is calculated as a company's profit divided by the outstanding shares of its common stock. The resulting number serves as an indicator of a company's profitability.Investors like companies with high profitability, and the market always rewards those earnings results that beat the estimates. Hope the following content helps you learn more about good companies.2.Weekly List of Stocks with Estim

TigerGPT Answer: ### Eli Lilly (LLY) Earnings Call Summary #### Forecast Data - **Earnings Per Share (EPS):** $2.70 (Q2 2024) - **Prior Year EPS:** $2.11 (Q2 2023) - **Percentage Change:** +27.96% - **Total Revenue:** $9,948,664,070.00 (Q2 2024) - **Prior Year Revenue:** $8,312,100,000.00 (Q2 2023) - **Percentage Change:** +19.68% - **EBIT:** $2,990,738,540.00 (Q2 2024) - **Prior Year EBIT:** $2,252,100,000.00 (Q2 2023) - **Percentage Change:** +32.82% **Significance:** The significant increases in EPS, total revenue, and EBIT indicate strong financial performance and growth for Eli Lilly compared to the same period last year. This suggests effective cost management and successful product sales. #### Quarterly Important News 1. **Negative Ne

I opened $Eli Lilly(LLY)$  ,Just like yesterday's trading update, I will continue to increase my position in LLY. I hope it can maintain its trend

When it comes to investing in 2024, Eli Lilly and Company (LLY) and the Vanguard S&P 500 ETF (VOO) present two very different avenues, each with its own set of benefits and risks. With LLY’s earnings report just around the corner on 8 August, it’s a perfect time to weigh up these two intriguing investment options. Strategising with precision: The art of forecasting stock market trends Eli Lilly’s Explosive Growth: Worth the Hype? Eli Lilly has had a stellar year so far, delivering a staggering 62.09% return year-to-date. This phenomenal performance can be largely credited to the soaring popularity of its weight loss medications, Mounjaro and Zepbound. With the pharmaceutical industry constantly evolving, LLY’s Q2 2024 revenue projection of $9.97 billion marks a hefty 20% increase from

I opened $Eli Lilly(LLY)$  ,The sharp declines in the U.S. stock market are often followed by rapid rebounds. I also regret not holding enough LLY shares, as I really like its trend. So today, I added a bit more to my position.

$Coinbase Global, Inc.(COIN)$ I’m looking at the daily turnover, it's not as good as the first quarter, the trend is not good, most of the profit is split by the ETF, it's already a short-term high now. So now I’m conflicted, what should I do, stay or leave?

Find out more here:Tiger BOSS Debit Card - BIG BOSS BASH! Grab your friends, win SGD 888*!

$Eli Lilly(LLY)$ $Hims & Hers Health Inc.(HIMS)$ $Novo-Nordisk A/S(NVO)$  Goldman has updated its market model for obesity therapeutics and now forecasts total worldwide sales of next-generation, primarily GLP-1 receptor agonist (incretin mimetic) anti-obesity medications to reach "$130B by 2030", INCREASE from the prior forecast of $100B

Eli Lilly has been having major wins since their earnings. They’re drugs are no longer in shortage, Zepound was found to have cardiovascular benefits, and their once a week insulin is showing equal results to daily insulin injections.The cardiovascular benefits from zepound is huge because patient insurances are more likely to cover drugs like this, without patients having to try other medications since it’s an actual benefit that no other fat loss meds have and it help lower the risk of their patients being in the hospital, which will save insurance companies more money at the end.The weekly insulin is HUGE. The biggest complaints patients have is the amount of times they have to inject themselves throughout the day. The benefit this will have, is that both type 1 and type 2 diabetics can

$Eli Lilly(LLY)$ is scheduled to report its results for period ending 30 June 2024 on 08 August 2024 before the market open. Market is expecting LLY to show a rise in quarterly revenue with a 19.3% increase in revenue to $9.919 billion from $8.31 billion compared to same period one year ago. Earnings per share estimate for Eli Lilly is $2.75. Benefit From Novo Weight Loss Medicine Wegovy Shortage While the Food and Drug Administration removed Eli Lilly's competing weight loss medicine Zepbound from its shortage list last week, most dosage versions of Wegovy remain in shortage. So this would be something that investors could be looking out for $Novo-Nordisk A/S(NVO)$ result reporting on Wednesday whether NV

When it comes to investing in 2024, Eli Lilly and Company (LLY) and the Vanguard S&P 500 ETF (VOO) present two very different avenues, each with its own set of benefits and risks. With LLY’s earnings report just around the corner on 8 August, it’s a perfect time to weigh up these two intriguing investment options. Strategising with precision: The art of forecasting stock market trends Eli Lilly’s Explosive Growth: Worth the Hype? Eli Lilly has had a stellar year so far, delivering a staggering 62.09% return year-to-date. This phenomenal performance can be largely credited to the soaring popularity of its weight loss medications, Mounjaro and Zepbound. With the pharmaceutical industry constantly evolving, LLY’s Q2 2024 revenue projection of $9.97 billion marks a hefty 20% increase from

TigerGPT Answer: ### Eli Lilly (LLY) Earnings Call Summary #### Forecast Data - **Earnings Per Share (EPS):** $2.70 (Q2 2024) - **Prior Year EPS:** $2.11 (Q2 2023) - **Percentage Change:** +27.96% - **Total Revenue:** $9,948,664,070.00 (Q2 2024) - **Prior Year Revenue:** $8,312,100,000.00 (Q2 2023) - **Percentage Change:** +19.68% - **EBIT:** $2,990,738,540.00 (Q2 2024) - **Prior Year EBIT:** $2,252,100,000.00 (Q2 2023) - **Percentage Change:** +32.82% **Significance:** The significant increases in EPS, total revenue, and EBIT indicate strong financial performance and growth for Eli Lilly compared to the same period last year. This suggests effective cost management and successful product sales. #### Quarterly Important News 1. **Negative Ne

😀Hi Tigers,We invite you to take a closer look at the possible winners by EPS in the Q2 earnings season.In this post, we have highlighted the top 20 stocks by market capitalization with an estimated higher EPS ahead of their earnings in the period from August 5 to August 9.1.Why EPS Matters?Earnings per share(EPS), refers to the income per share brought to investors/shareholders in the open market.EPS is calculated as a company's profit divided by the outstanding shares of its common stock. The resulting number serves as an indicator of a company's profitability.Investors like companies with high profitability, and the market always rewards those earnings results that beat the estimates. Hope the following content helps you learn more about good companies.2.Weekly List of Stocks with Estim

$Eli Lilly(LLY)$ Now it's time for some facts.Lly Earnings are forecasted to increase for the next 2 quarters going forward.Based on analyst ratings, Eli Lilly’s 12 month average price target is $943.00 Eli Lilly has a 17% upside potential based on the analysts' average target price and the current price of $804. Now I believe this analyst rating may have occurred before the price drop. Based on the original 7.3% upside, the stock was probably around $880 a share when they were calculating the upside potential. On the low side I have seen other analysts who say the average Target prices $858 a share. Still with a 7% upside potential.Regardless, that should not change the outlook consensus which is based on sales projections. so in theory, the upsid

$Novo-Nordisk A/S(NVO)$ This feels undervalued compared to $Eli Lilly(LLY)$ LLY. Little debt, yearly earnings exceeding 50B (10x that of LLY for ‘23). I get LLY has other drugs in the pipeline aside from weight loss / diabetes, but they don’t seem as lucrative as the weight loss market. Anyone know why else LLY is valued much higher other than the fact it’s a US company? Not saying comparatively LLY is a bad choice, just that NVO books look better. LLY sales as much as PFE and its value is like 5X of PFE. NVO seems slightly undervalued but LLY definitely way overvalued.

$Eli Lilly(LLY)$ In Big Pharma's growth rankings Eli Lilly took top spot away from Novo Nordisk in Q1and they will do it again in Q2.NVO $Novo-Nordisk A/S(NVO)$ missed. Lilly won't missFacts matter! Look at last quarter to see how it played out.Q1: Novo Nordisk dropped out of the top spot with its 22% YOY increaseLilly took over as No. 1 thanks to its 28% quarterly boost.They will do it again and beat NVOThink Winnie The Pooh GIF

$Novo-Nordisk A/S(NVO)$ Earnings today -estimates are upbeat for - revenue beat - earnings beat - improved GRoss Profit- guidance upgrade based of improved supply chain - so the key are any new disclosures on new market launches, acquisition update and new FDA approvals - feels positive -time for upside surprise and make shorts scramble 👍🏻😁

$Novo-Nordisk A/S(NVO)$ Definitely undervalued. The market makers are finding a reason to push the price down. Sales of Ozempic & Wegovy are still pretty stellar. Missed analyst estimates??!! Come on.🙄 Be patient. There's a reason why prices are being pushed down. Definitely bullish.

Considering Novo Nordisk (NVO) and Eli Lilly (LLY) before earnings? Both have strong growth prospects, especially in diabetes care. Assess their financials and market position for a potentially rewarding investment. [Great][Great][Great]$Novo-Nordisk A/S(NVO)$ $Eli Lilly(LLY)$

$Eli Lilly(LLY)$  Earnings out pre market on 8 aug. $LLY will continue to dominate the obesity market and associated secondary indications over time. Company has the lead and has now become the most valuable large cap biotech company.  Invest in the winner 🏆 

$Eli Lilly(LLY)$  Wow. Double beat. Previous Full Year guide up now guiding up again.  India approval.  What's coming next? Stock split?

Buy both. No need to choose

I opened $Eli Lilly(LLY)$  ,The sharp declines in the U.S. stock market are often followed by rapid rebounds. I also regret not holding enough LLY shares, as I really like its trend. So today, I added a bit more to my position.

I opened $Eli Lilly(LLY)$  ,Just like yesterday's trading update, I will continue to increase my position in LLY. I hope it can maintain its trend

🌟🌟🌟The  Global Weight Management Market size is calculated at USD 160.15 billion  in 2024 and is expected to reach USD 328.24 billion by 2032, growing at a CAGR of 8.3% from 2024 to 2032. Roundhill Investment has just launched $Roundhill GLP-1 & Weight Loss ETF(OZEM)$ on May 21 to capture this growing market.  OZEM is the world 's first GLP-1 and Weight Loss ETF. GLP-1 is a revolutionary treatment which reduces food intake, appetite and hunger and promotes fullness and satiety with the ultimate result of promoting weight loss.  Groundbreaking GLP-1 treatments such as Wegovy by Novo-Nordisk and Ozempic by Eli Lilly are leading medical advancement in weight management. The Top 10 holdings include 

$SATS LTD.(S58.SI)$  SATS Soars: Record Revenue and Profit Signal Takeoff for Aviation Industry Leader SATS Ltd. (SATS), the Singaporean aviation services giant, has reported a remarkable turnaround, posting a full-year profit of S$56.4 million for FY24. This stellar performance follows a year of losses and signifies a strong recovery fueled by the aviation sector's rebound and the successful integration of Worldwide Flight Services (WFS). Record-breaking Revenue: SATS' revenue tripled to a record S$5.1 billion in FY24, a clear reflection of the aviation industry's resurgence. This growth is further bolstered by the consolidation with WFS, a strategic move that is already delivering significant synergies. The integ

$Eli Lilly(LLY)$ $Novo-Nordisk A/S(NVO)$   Bullish Factors:Strong Performance:  1. Companies like Eli Lilly (LLY) and Novo Nordisk (NVO) have seen significant stock price increases (90% and 80% respectively) over the past two years, indicating strong market performance and investor confidence. 2. Market Demand: The increasing demand for effective weight-loss solutions provides a growing market for these companies. 3. Innovation: Hims' plan to offer weight-loss drugs at a significant discount compared to competitors like Wegovy indicates potential for disruption and market share gains. Considerations: 1. Valuation: High stock prices may reflect current market optimism, potentially limiting immediat